WATERTOWN, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic ...
MANILA, Philippines - The catchy “3-in-1 plus 1” jingle for the latest Selecta ice cream TV ad could well be a subtle reference to what the company, Unilever RFM Ice Cream Inc., has accomplished over ...
Spark Therapeutics has gained exclusive worldwide rights to Selecta Biosciences’ Synthetic Vaccine Particles (SVP™) platform and exclusive options for up to four additional undisclosed genetic targets ...
(RTTNews) - Selecta Biosciences Inc. (SELB) expects topline data from the Phase 3 DISSOLVE clinical program investigating SEL-212 in chronic refractory gout in the first-quarter of 2023. The company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results